1. Pulmonary Arterial Hypertension and Hospitalizations

2. High-Risk Patients Have Worse Outcomes

3. REVEAL Registry Hospitalizations and Outcomes

4. Risk Factors for PAH-Related Hospitalization

5. PAH-Related Events Associated With Clinical Outcomes and Mortality Landmark Analysis

6. Definition of Morbidity Events in SERAPHIN and GRIPHON

7. Association Between Morbidity and Mortality at Any Landmark Time Point*

8. GRIPHON Predictive Value of Hospitalization and Disease Progression

9. SERAPHIN Post-Hoc Analyses Time to First PAH-Related Hospitalization

10. Emotional and Overall Quality of Life Considerations

11. AMBITION Trial: Confirmed Benefit of Upfront Combination Therapy

12. ESC/ERS Risk Assessment for Initial Treatment Approach in PAH

13. Continual Re-Assessment Structured Follow-Up

14. Individual and Multiparameter Risk Assessment Is Needed

15. Achieving Low-Risk Status in PAH

16. French Registry: Low-Risk Criteria Determines Long-Term Prognosis

17. French Registry: BNP Subset Analysis

18. Importance of Risk Assessment in French Registry

19. REVEAL Risk Score 2.0

20. REVEAL Risk Score 2.0 What Has Changed?

21. Goal: Get Your Patient to a Low-Risk Status

22. Palliative Care in PAH: Component of Whole Team Approach

23. General Measures

24. Multidisciplinary Approach to Care

25. Coordination of Local and PH Center of Care Collaborative Approach

26. Use of Technology and Virtual Visits to Co-Manage Patients

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)